Test Price
1,900 AEDโ Home Collection Available
PD-L1 22C3 Immunohistochemistry Test in Dubai
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- Specimen Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval for archival blocks and slides.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation.
- Insurance Support: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The PD-L1 22C3 immunohistochemistry test detects programmed death-ligand 1 expression using the validated 22C3 antibody clone, enabling clinicians to identify patients most likely to benefit from pembrolizumab immunotherapy. This assay is performed on formalin-fixed paraffin-embedded (FFPE) tissue specimens using an automated Dako platform, ensuring reproducible and quantitative scoring.
| Feature | Our Test (PD-L1 22C3) | Closest Alternative (SP142 Assay) |
|---|---|---|
| Precision | High-affinity 22C3 clone, FDA-validated for pembrolizumab | SP142 clone, validated for atezolizumab; lower concordance with pembrolizumab |
| Methodology | IHC on FFPE tissue, automated Dako platform | IHC, manual interpretation, different antibody |
| Turnaround Speed | 5 working days (block) / 5โ7 working days (tissue biopsy) | 7โ10 working days (variable) |
Physician Insight & Safety Protocols
Mr. Prabhakar Reddy Kalathoor โ Specialist Diagnostic Radiology (DHA Registration ID: 61713011) emphasizes: โThe PD-L1 22C3 result guides critical immunotherapy decisions. It must be interpreted alongside histopathology and clinical context. Always discuss the implications with your oncologist before adjusting any treatment plan.โ
Advisory Summary
Do not discontinue or alter prescribed cancer therapy without your treating physicianโs approval. This test is a supplement to, not a replacement for, comprehensive oncologic care.
Exclusion Criteria & Safety Red Flags
- Inadequate tumor content in the sample, or specimen not properly processed as an FFPE block.
- Unlabeled or mislabeled specimens that cannot be reliably traced.
- Patient experiencing acute bleeding or complications from biopsy site: seek emergency medical attention immediately.
Patient FAQ & Clinical Guidance
1. What is the purpose of the PD-L1 22C3 test?
The test measures PD-L1 protein expression to determine eligibility for pembrolizumab immunotherapy in cancers such as non-small cell lung cancer and head/neck squamous cell carcinoma. Results help personalize treatment decisions and avoid ineffective therapies.
2. How should I prepare for the test?
No special fasting or medication changes are required. Simply ensure your biopsy tissue is processed as an FFPE block and accompanied by the relevant histopathology report and clinical history for accurate interpretation.
3. How long does it take to get results?
Results are typically reported within 5 working days for paraffin blocks and 5โ7 working days for larger tissue resections, enabling timely immunotherapy planning.
UAE Regulatory & Data Privacy Adherence
Legal Mandates: This service complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), Federal Law No. 2 of 2019 Concerning the Use of ICT in Health Fields, and Federal Decree-Law No. 4 of 2016 on Medical Liability. Our laboratory operates under ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139).
Facility License: DHA License No. 1143. All procedures adhere to DHA and MOHAP standards.
Clinical & Logistical Metadata
| Test Name | PD-L1 22C3 Immunohistochemistry |
| Price (AED) | 1,900 AED |
| Turnaround Time | 5โ7 working days |
| Sample Type / Matrix | Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Block or Biopsy Slides. Secure Medical Courier Solid Tissue Specimen Retrieval. |
| Methodology Used | Immunohistochemistry (IHC), 22C3 antibody clone, automated Dako platform |
| ICD-10-CM Code | C34.9 (Malignant neoplasm of bronchus or lung, unspecified), C32.9 (Malignant neoplasm of larynx, unspecified), C09.0 (Malignant neoplasm of tonsil) |
| LOINC Code | 92818-8 |
| DHA Facility License & Laboratory Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians